Introduction: The capability to diagnose pathologically morbid adherent placenta has transformed over the preceding era. Depending on the knowledge and availability of equipment, ultrasound (ultrasound), MRI or a combination of these methods are currently used. Ultrasound is popular for its low cost and availability, and is broadly used to detect location of placental and possible anomalous growth. Place and Duration: In the Gynecology Department of Civil Hospital Quetta for six-months duration from March 2021 to September 2021 Methods: 72 total pregnant women booked on the third trimester of pregnancy (diagnosed with early ultrasound) with diagnosis of the placenta previa were selected. Women in the primigravid group and females with pregnancies complicated by heart disease, diabetes and hypertension were omitted from the analysis. Color Doppler ultrasound was performed in all patients and the absence or presence of morbidly adherent placenta previa was detected. The results of the color Doppler ultrasound examination were correlated with the results of the surgical treatment (concluding it as the gold standard). Results: 28.21 ± 2.70 years was the mean age of the patients. Ultrasound revealed MAP in 9 (12.5%) females. The ultrasound positive patients had 08 true positives and 01 false positives. Of the 63 ultrasound negative patients, 61 were true negative (P≤0.05) and false negative patients were two patients. The calculated specificity, sensitivity, negative and positive predictive value and analytical accurateness of the color Doppler test in the prenatal MAP diagnosis were rated at 97.21%,86.8%, 97.89%, 86.8%% and 98.95%, respectively. Conclusions: In this study, it was found that the diagnostic accurateness of color Doppler ultrasound is higher in the prenatal analysis of morbidly adherent placenta in pregnant women with placenta previa. Keywords: Sensitivity, non-invasive imaging modality and Placenta accreta
Aim: To establish the role of 1st trimester ultrasound in detecting fetal abnormalities by performing a 20-week ultrasound scan as a standard. Study Design: A cross-sectional descriptive study. Methods: A total of 380 cases were recruited from the Obstetrics and Gynecology department of Jinnah post graduate medical center Karachi for six months duration from January, 2021 to June, 2021. The patients were assessed at 11-14 weeks of pregnancy for the diagnosis of fetal anomalies in high-risk women taking 20 weeks gestation ultrasound scan as the gold standard. Results: Out of 380 women, mean age was 27.47 ± 2.57 years. 238 (62.6%) women underwent ultrasound at 12 + 13 weeks and 142 (37.4%) women had it at the 10-11 weeks of amenorrhea. Regarding maternal risk factors, 46 (12.1%) women had advanced maternal age> 35 years, 21 (5.5%) women with a family history of chromosomal abnormalities, 4 (2.1%) with a history of Down syndrome in previous babies, 118 (30.8)%) women with a history of congenital abnormalities, 85 (21.6%) women with a previous pregnancy complicated by spontaneous abortion, 11 (3.4%) women with a previous child with cerebral palsy, 56 (14.2%) women with previous intrauterine death, 13 (3.4%) women with a history of thalassemia, 7 (1.8%) women with a history of multiple pregnancies and 22 (5.5%) women with associated medical complications; diabetes, hypertension. The sensitivity, specificity and predictive value of ultrasound in the diagnosis of fetal defects in high-risk women compared to the ultrasound at week 20 showed 91.9% sensitivity, 100% specificity, 100% positive predictive value and negative predictive value is 96.27%, and the diagnostic accuracy is 99.2%. Conclusion: First trimester ultrasound is effective in detecting fetal anomalies. Keywords: First trimester ultrasound, fetal anomaly, high-risk women
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.